Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

32 та иш

Иш: Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis

  1. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011

    Dilrabo Ulmasova, G Uzakova, M N Tillyashayhov +17

    МақолаTuberculosis Research and EpidemiologyEurosurveillance201315 иқтибос
    ABI

  2. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

    Armand Van Deun, Aung Kya Jai Maug, Md Abdul Hamid Salim +4

    Мақола201011 иқтибос
    ABI

  3. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

    Andrew Nunn, Patrick Phillips, Sarah Meredith +16

    Мақола20196 иқтибос
    ABI

  4. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries

    Arnaud Trébucq, V Schwoebel, Zacharie Kashongwe +15

    Мақола20176 иқтибос
    ABI

  5. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

    K. J. M. Aung, Armand Van Deun, Erik De Clercq +4

    Мақола20145 иқтибос
    ABI

  6. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study

    Elisabeth Sánchez-Padilla, Caroline Marquer, Stobdan Kalon +5

    Мақола20145 иқтибос
    ABI

  7. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

    Faiz Ahmad Khan, M Salim, Philipp du Cros +9

    Шарҳ мақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 иқтибос
    ABI

  8. “When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention

    Kalpita Shringarpure, Petros Isaakidis, Karuna D. Sagili +3

    Мақола20163 иқтибос
    ABI

  9. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

    Surendra K. Sharma, Keertan Dheda

    Таҳририят мақоласи20193 иқтибос
    ABI

  10. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data

    Andrei Dadu, Arax Hovhannesyan, Sevim Ahmedov +2

    Мақола20192 иқтибос
    ABI

  11. Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

    Giovanni Sotgiu, Simon Tiberi, Rosella Centis +4

    Мақола20162 иқтибос
    ABI

  12. RAWGraphs

    Michele Mauri, Tommaso Elli, Giorgio Caviglia +2

    Мақола20172 иқтибос
    ABI

  13. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

    S.K. Abidi, Jay Achar, M.M. Assao Neino +34

    МақолаTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 иқтибос
    ABI

  14. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  15. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  16. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

    Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

    МақолаTuberculosis Research and EpidemiologyERJ Open Research20201 иқтибос
    ABI